Role of microRNAs in obesity and the metabolic syndrome
- PMID: 19793375
- DOI: 10.1111/j.1467-789X.2009.00659.x
Role of microRNAs in obesity and the metabolic syndrome
Abstract
Obesity and the metabolic syndrome are major public health concerns, and present a formidable therapeutic challenge. Many patients remain recalcitrant to conventional lifestyle changes and medical therapies. Bariatric surgery has made laudable progress in the treatment of obesity and its related metabolic disorders, yet carries inherent risks. Unravelling the molecular mechanisms of metabolic disorders is essential in order to develop novel, valid therapeutic strategies. Mi(cro)RNAs play important regulatory roles in a variety of biological processes including adipocyte differentiation, metabolic integration, insulin resistance and appetite regulation. Investigation of these molecules and their genetic targets may potentially identify new pathways involved in complex metabolic disease processes, improving our understanding of metabolic disorders and influence future approaches to the treatment of obesity. This review discusses the role of miRNAs in obesity and related components of the metabolic syndrome, and highlights the potential of using miRNAs as novel biomarkers and therapeutic targets for these diseases.
Similar articles
-
Plasma cell membrane glycoprotein 1 (PC-1): a marker of insulin resistance in obesity, uremia and diabetes mellitus.Clin Lab. 2004;50(5-6):271-8. Clin Lab. 2004. PMID: 15209435 Review.
-
Brain insulin, energy and glucose homeostasis; genes, environment and metabolic pathologies.Eur J Pharmacol. 2008 May 6;585(1):38-49. doi: 10.1016/j.ejphar.2008.01.050. Epub 2008 Feb 29. Eur J Pharmacol. 2008. PMID: 18407262 Review.
-
The insulin resistance syndrome: mechanisms of clustering of cardiovascular risk.Semin Vasc Med. 2002 Feb;2(1):45-57. doi: 10.1055/s-2002-23095. Semin Vasc Med. 2002. PMID: 16222595 Review.
-
microRNAs and the regulation of glucose and lipid metabolism.Diabetes Obes Metab. 2007 Nov;9 Suppl 2:67-73. doi: 10.1111/j.1463-1326.2007.00775.x. Diabetes Obes Metab. 2007. PMID: 17919180 Review.
-
The metabolic syndrome: metabolic changes with vascular consequences.Eur J Clin Invest. 2007 Jan;37(1):8-17. doi: 10.1111/j.1365-2362.2007.01755.x. Eur J Clin Invest. 2007. PMID: 17181562
Cited by
-
Differential expression of microRNAs in adipose tissue after long-term high-fat diet-induced obesity in mice.PLoS One. 2012;7(4):e34872. doi: 10.1371/journal.pone.0034872. Epub 2012 Apr 4. PLoS One. 2012. PMID: 22496873 Free PMC article.
-
The pre-mir-27a variant rs895819 may contribute to type 2 diabetes mellitus susceptibility in an Iranian cohort.J Endocrinol Invest. 2016 Oct;39(10):1187-93. doi: 10.1007/s40618-016-0499-4. Epub 2016 Jun 14. J Endocrinol Invest. 2016. PMID: 27300034
-
BMSCs and miR-124a ameliorated diabetic nephropathy via inhibiting notch signalling pathway.J Cell Mol Med. 2018 Oct;22(10):4840-4855. doi: 10.1111/jcmm.13747. Epub 2018 Jul 19. J Cell Mol Med. 2018. PMID: 30024097 Free PMC article.
-
Stress in obesity and associated metabolic and cardiovascular disorders.Scientifica (Cairo). 2012;2012:205027. doi: 10.6064/2012/205027. Epub 2012 Dec 31. Scientifica (Cairo). 2012. PMID: 24278677 Free PMC article. Review.
-
Prognostic Value of MicroRNAs in Coronary Artery Diseases: A Meta-Analysis.Yonsei Med J. 2018 Jun;59(4):495-500. doi: 10.3349/ymj.2018.59.4.495. Yonsei Med J. 2018. PMID: 29749132 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical